Histotype
Leukemia [B-ALL]
| Parameter | Information |
|---|---|
| Strain | NSG |
| Implant Type | Cells |
| Implant Location | IV |
| Time to Staging | 3 days |
| Time to Evaluation Size (days) | ~22 days |
| Td | 1.3 days |
The above parameters are from one study. For further information on this cell line and other parameters, including different strains, vendors, implant type and location and/or standards of care, please contact us.
Tumor Line
Human
Ref #
9224
Spotlight on ALM6-Luc: Adult B Acute Lymphoblastic Leukemia
Learn more about this cell line in our scientific spotlights:
Acute lymphoblastic leukemia (ALL) is a cancer of the lymphoid lineage characterized by the development of increased numbers of immature lymphocytes. ALL is a relatively rare cancer, representing less than 0.5% of all cancers in the United States, with the American Cancer Society estimating approximately 5,930 new cases and 1,500 deaths from ALL in the United States for 2019. However, the fact that ALL is the most common childhood cancer makes it of interest to researchers. The risk for developing ALL is highest in children younger than 5 years of age. This risk then declines slowly until the mid-20s before it begins to rise again after age 50. While most cases of ALL occur in children, most deaths from ALL occur in adults. Standard therapies for ALL include the use of aggressive or long-term chemotherapy. These treatment regimens result in 90% of children surviving after five years. However, this drops to around 40% of adult patients remaining disease free. Due to this relapse rate in ALL, other treatment options have been sought.